Nektar Therapeutics buy BTIG Research
Start price
30.09.24
/
50%
€1.17
Target price
30.09.25
€3.58
Performance (%)
-50.21%
End price
01.10.25
-
Summary
This prediction is currently being closed. The BUY prediction by BTIG_Research for Nektar Therapeutics is performing very badly with a performance of -50.21%. BTIG_Research has a follow-up prediction for Nektar Therapeutics where he still thinks Nektar Therapeutics is a Buy. BTIG_Research has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | 0.795% | 1.458% | 17.980% |
| iShares Nasdaq 100 | -3.088% | -0.762% | 3.169% |
| iShares Nikkei 225® | -0.952% | -2.268% | 12.208% |
| iShares S&P 500 | -1.393% | 0.199% | 1.698% |
Comments by BTIG_Research for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $4.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von BTIG_Research gewählte maximale Laufzeit wurde überschritten